Announcements Trials
Browse Landscape

Phase

Phase NA 9Phase 2 5Phase EARLY_PHASE1 3Phase 4 2Phase 1/2 2Phase 3 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Skin Neoplasms 1Neoplasms 1Melanoma 1Breast Neoplasms 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Fluorescein × Clear all
NCT00847522 2017-12-20

Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma

University of Utah

Phase 1/2 Completed
90 enrolled 7 charts
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

NCT01614184 2013-07-10

Fluorescein for Sentinel Lymph Node Biopsy (SLNB) in Breast Cancer

University of Utah

Phase 1/2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡